## Joyce Wing Yan Mak

## List of Publications by Citations

Source: https://exaly.com/author-pdf/106188/joyce-wing-yan-mak-publications-by-citations.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

33 431 9 20 g-index

47 854 6.9 4.67 ext. papers ext. citations avg, IF L-index

#	Paper	IF	Citations
33	Probiotics and COVID-19: one size does not fit all. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2020</b> , 5, 644-645	18.8	99
32	The epidemiology of inflammatory bowel disease: East meets west. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2020</b> , 35, 380-389	4	91
31	Gut microbiota dynamics in a prospective cohort of patients with post-acute COVID-19 syndrome <i>Gut</i> , <b>2022</b> ,	19.2	41
30	The gut microbiome: an under-recognised contributor to the COVID-19 pandemic?. <i>Therapeutic Advances in Gastroenterology</i> , <b>2020</b> , 13, 1756284820974914	4.7	25
29	Microbiota engraftment after faecal microbiota transplantation in obese subjects with type 2 diabetes: a 24-week, double-blind, randomised controlled trial. <i>Gut</i> , <b>2021</b> ,	19.2	19
28	Elucidation of Proteus mirabilis as a Key Bacterium in Crohn's Disease Inflammation. <i>Gastroenterology</i> , <b>2021</b> , 160, 317-330.e11	13.3	17
27	Review article: bugs, inflammation and mood-a microbiota-based approach to psychiatric symptoms in inflammatory bowel diseases. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 52, 247-2	.66 <sup>.1</sup>	15
26	Challenges in the diagnosis and management of inflammatory bowel disease in resource-limited settings in Asia. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2020</b> , 5, 1076-1088	18.8	11
25	Zero COVID-19 infection in inflammatory bowel disease patients: Findings from population-based inflammatory bowel disease registries in Hong Kong and Taiwan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2021</b> , 36, 171-173	4	10
24	COVID-19 Pandemic: Which IBD Patients Need to Be Scoped-Who Gets Scoped Now, Who Can Wait, and how to Resume to Normal. <i>Journal of Crohn's and Colitis</i> , <b>2020</b> , 14, S791-S797	1.5	9
23	Epidemiology and Natural History of Elderly-onset Inflammatory Bowel Disease: Results From a Territory-wide Hong Kong IBD Registry. <i>Journal of Crohns and Colitis</i> , <b>2021</b> , 15, 401-408	1.5	9
22	Significant Medical and Surgical Morbidity in Perianal Crohn's Disease: Results from a Territory-Wide Study. <i>Journal of Crohn</i> and Colitis, <b>2018</b> , 12, 1392-1398	1.5	9
21	Territory-wide population-based study of chronic hepatitis C infection and implications for hepatitis elimination in Hong Kong. <i>Liver International</i> , <b>2018</b> , 38, 1911-1919	7.9	8
20	Cancer risk and chemoprevention in Chinese inflammatory bowel disease patients: a population-based cohort study. <i>Scandinavian Journal of Gastroenterology</i> , <b>2020</b> , 55, 279-286	2.4	7
19	Risks of post-colonoscopic polypectomy bleeding and thromboembolism with warfarin and direct oral anticoagulants: a population-based analysis. <i>Gut</i> , <b>2022</b> , 71, 100-110	19.2	7
18	Stopping anti-tumour necrosis factor therapy in patients with perianal Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 50, 1195-1203	6.1	6
17	No Systemic Lupus Erythematosus with COVID-19 in Hong Kong: The Effect of Masking?. <i>Journal of Rheumatology</i> , <b>2020</b> , 47, 1591	4.1	6

## LIST OF PUBLICATIONS

16	Modulation of gut microbiota protects against viral respiratory tract infections: a systematic review of animal and clinical studies. <i>European Journal of Nutrition</i> , <b>2021</b> , 60, 4151-4174	5.2	6
15	A novel gut microbiota-derived synbiotic formula (SIM01) as an adjuvant therapy for COVID-19: An open-label pilot study <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2022</b> ,	4	6
14	P788 Significant medical and surgical morbidity in perianal Crohn disease: Results from a population-based study. <i>Journal of Crohn and Colitis</i> , <b>2018</b> , 12, S510-S510	1.5	5
13	In Patients With Perianal Crohn's Fistulas, What Are the Outcomes When 'Radiological Healing' Is Achieved? Does Radiological Healing of Perianal Crohn's Fistulas Herald the Time Point for Stopping a Biologic?. <i>Journal of Crohn's and Colitis</i> , <b>2017</b> , 11, 1506	1.5	5
12	Probiotics and COVID-19 - Authors' reply. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2020</b> , 5, 722-723	3 18.8	4
11	Epidemiology of fibrostenosing inflammatory bowel disease. <i>Journal of Digestive Diseases</i> , <b>2020</b> , 21, 332-335	3.3	4
10	High prevalence of extended-spectrum beta-lactamase organisms and the COVID-19 pandemic impact on donor recruitment for fecal microbiota transplantation in Hong[Kong. <i>United European Gastroenterology Journal</i> , <b>2021</b> , 9, 1027-1038	5.3	3
9	Optimising management strategies of inflammatory bowel disease in resource-limited settings in Asia. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2020</b> , 5, 1089-1100	18.8	2
8	Impact of Physicians' and Patients' Compliance on Outcomes of Colonoscopic Polypectomy With Anti-Thrombotic Therapy. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 2559-2566.e1	6.9	2
7	Hepatobiliary and Pancreatic: A tree in the liver. <i>Journal of Gastroenterology and Hepatology</i> (Australia), <b>2021</b> , 36, 2337	4	1
6	Stopping 5-Aminosalicylic Acid in Ulcerative Colitis Patients in Corticosteroid-free remission is not associated with Increased Risk of Flare: A Territory-wide population-based cohort study <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2022</b> ,	4	1
5	Probiotic supplementation demonstrates therapeutic potential in treating gut dysbiosis and improving neurocognitive function in age-related dementia <i>European Journal of Nutrition</i> , <b>2022</b> , 1	5.2	O
4	COVID-19 Outcomes Among Racial and Ethnic Minority Individuals With Inflammatory Bowel Disease in the United States. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 2210-2213.e3	6.9	О
3	P627 Stopping anti-tumour necrosis factor (TNF) therapy in patients with perianal Crohn disease: Results from a population-based study. <i>Journal of Crohn and Colitis</i> , <b>2019</b> , 13, S431-S431	1.5	
2	Use of Proton-Pump Inhibitor Is Not Associated with Adverse Clinical Outcomes in COVID-19 Patients: A Territory-Wide Cohort Study. <i>GastroHep</i> , <b>2022</b> , 2022, 1-13	1	
1	Twenty years of biological therapy in an patient with IBD. BMJ Case Reports, 2018, 2018,	0.9	